Brief intro:
- Author: Tao Wang, Jian-Cheng Liao, Xu Wang, Qing-Song Wang, Kai-Ying Wan, Yi-Yi Yang, Qing He, Jia-Xuan Zhang, Gong Chen, and Wen Li
- Journal: Neural Regen Res
- Doi: https://www.doi.org/10.4103/1673-5374.325747
- Publication Date: 2021 Dec 10
Products/Services used in the paper
Quotation shows PackGene:For the in vivo experiments, single stranded adenovirusassociated viruses were used. A short version of the human glial fibrillary acidic protein (GFAP) promoter (681 bp, provided by PackGene Biotech) was used to construct pAAV GFAP::GFP and pAAV GFAP::NeuroD1-P2A-GFP. AAV serotype 9 (AAV9) was produced by PackGene Biotech. Iodixanol gradient (Merck/Sigma-Aldrich, St Louis, MO, USA) ultracentrifugation was used for AAV purification. All AAV used in this study was diluted in 0.001% Pluronic F-68 solution (Poloxamer 188 Solution, Caisson Laboratories, Smithfield, UT, USA).
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Thirty adult male wild-type FVB/NJ mice (8–10 weeks old, ~25 g) were used for the in vivo experiments. Fifteen postnatal (P0–3) Sprague-Dawley rats were used for isolating primary astrocytes for in vitro experiments.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
